Translation of Research Outcomes into Clinical Benefits for the Community
The Menzies Research Institute is dedicated to the discovery of novel drug targets, drug candidates, assay methodologies, medical devices and diagnostic tools that will help those suffering from specific diseases and ultimately save lives. Menzies actively seeks commercial partners for its discovery-stage technologies.
We are currently seeking industry/research partners for the following projects:
Drug Targets/Candidates
Alzheimer's Disease
RAP (Receptor-Associated Protein)-Based Modulation of Aß Aggregation
Work currently ongoing at the Menzies Research Institute and Monash University, using RAP-based technology, has demonstrated a direct modulation of Aβ activity in vitro and in vivo. The research has shown a clear down regulation in Aβ aggregation, reducing the neurotoxic ability of Aβ to induce memory loss or cognitive impairment in an animal model of Alzheimer's Disease. This work is being used as the basis for developing viable drug candidates.
Stimulation of Neural Regeneration and Neural Targeting Using a Novel Molecule
The Menzies Research Institute has identified a small molecule able to stimulate neural regeneration and affect neural targeting. The Institute is looking for commercial partners to progress this technology.
Susceptibility Genes
Prostate Cancer
Gene SNPs Predictive of Prostate Cancer Risk
The Institute has identified a novel putative prostate cancer susceptibility gene on chromosome 5. The gene identified is ITGA2, which codes for the α2 subunit of the integrin α2β1 receptor. The institute has established that selected polymorphisms within the ITGA2 gene are significantly associated with prostate cancer risk. The SNPs also have an association with metastatic disease.
Assay and Analysis Services
Ultrasound Model to Detect Alterations in Microvascular Perfusion in Muscle
The Institute has developed a novel, non-invasive method to detect changes in microvascular perfusion in muscle. The method is highly relevant to testing the efficacy of therapeutics for Diabetes Type II, Peripheral Arterial Disease, Retinopathy and other related conditions.
Assessment of Neural Regeneration Activity in a Live Cell Assay
The Institute has developed a novel assay methodology for assessing the efficacy of molecules in inducing neural regeneration.
DNA Mutation Detection Using Mass Spectrometric Separation
The Institute has developed a novel method to detect DNA mutations using mass spectrometric analysis of oligonucleotide fragments. The method would also be suitable for developing a high throughput sequencing methodology. The Institute is seeking an industry partner to develop a commercial sequencing technique using this IP.
For further information on any of the research projects or services outlined below please contact:
Commercialisation Manager
Mobile: 0400 668 606
